BET inhibitors ( BETi ) influence oxidative phosphorylation metabolism by affecting mitochondrial dynamics leading to alterations in apoptotic pathways in triple‐negative breast cancer ( TNBC ) cells
Cell Proliferation · 2024
DOI: 10.1111/cpr.13730 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Proliferation, 2024. Verfasst von Teresa Rossi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Translational Research, AUSL-IRCCS di Reggio Emilia, Reggio Emila, Italy. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Oxidative Phosphorylation, Mitochondrial Dynamics, Apoptosis. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute, Fondazione AIRC per la Ricerca sul Cancro, NextGenerationEU.
Abstract (Originalsprache)
Repressing BET proteins' function using bromodomain inhibitors (BETi) has been shown to elicit antitumor effects by regulating the transcription of genes downstream of BRD4. We previously showed that BETi promoted cell death of triple‐negative breast cancer (TNBC) cells. Here, we proved that BETi induce altered mitochondrial dynamics fitness in TNBC cells falling in cell death. We demonstrated that BETi treatment downregulated the expression of BCL‐2, and proteins involved in mitochondrial fission and increased fused mitochondria. Impaired mitochondrial fission affected oxidative phosphorylation (OXPHOS) inducing the expression of OXPHOS‐related genes, SDHa and ATP5a, and increased cell death. Consistently, the amount of mitochondrial DNA and mitochondrial membrane potential (∆Ψm) increased in BETi‐treated cells compared to control cells. Lastly, BETi in combination with Metformin reduced cell growth. Our results indicate that mitochondrial dynamics and OXPHOS metabolism support breast cancer proliferation and represent novel BETi downstream targets in TNBC cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Translational Research, AUSL-IRCCS di Reggio Emilia, Reggio Emila, Italy.
- High Resolution NMR Unit, Core Facilities, Istituto Superiore di Sanità, Rome, Italy.
- Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, Catanzaro, Italy.
- Department of Biology, Ecology and Earth Sciences, Centre for Microscopy and Microanalysis (CM2), University of Calabria, Cosenza, Italy.
- Epilepsy Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
- Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy.
ORCID-Profile: Teresa Rossi, Mariaelena Pistoni
Förderung
- Ministero della Salute
- Fondazione AIRC per la Ricerca sul Cancro
- NextGenerationEU
Zitieren
APA
Rossi, T., Iorio, E., Chirico, M., Pisanu, M. E., Amodio, N., Cantafio, M. E. G., Perrotta, I., Colciaghi, F., Fiorillo, M., Gianferrari, A., Puccio, N., Neri, A., Ciarrocchi, A., & Pistoni, M. (2024). BET inhibitors ( BETi ) influence oxidative phosphorylation metabolism by affecting mitochondrial dynamics leading to alterations in apoptotic pathways in triple‐negative breast cancer ( TNBC ) cells. Cell Proliferation. https://doi.org/10.1111/cpr.13730
Vancouver
Rossi T, Iorio E, Chirico M, Pisanu ME, Amodio N, Cantafio MEG, et al. BET inhibitors ( BETi ) influence oxidative phosphorylation metabolism by affecting mitochondrial dynamics leading to alterations in apoptotic pathways in triple‐negative breast cancer ( TNBC ) cells. Cell Proliferation. 2024. doi:10.1111/cpr.13730
BibTeX
@article{Rossi2024,
author = {Rossi, Teresa and Iorio, Egidio and Chirico, Mattea and Pisanu, Maria Elena and Amodio, Nicola and Cantafio, Maria Eugenia Gallo and Perrotta, Ida and Colciaghi, Francesca and Fiorillo, Marco and Gianferrari, Alessia and Puccio, Noemi and Neri, Antonino and Ciarrocchi, Alessia and Pistoni, Mariaelena},
title = {BET inhibitors ( BETi ) influence oxidative phosphorylation metabolism by affecting mitochondrial dynamics leading to alterations in apoptotic pathways in triple‐negative breast cancer ( TNBC ) cells},
journal = {Cell Proliferation},
year = {2024},
doi = {10.1111/cpr.13730}
}
EUVIMED